\-\ Texto\\:\\ \ \(0\)\
\-\ diffusely\\ decreased\\ breath\\ sounds\\ with\\ dry\\ crackles\\ and\\ a\\ restrictive\\ pattern\\ on\\ pulmonary\\ function\\ tests\\.\ \(0\)\
\-\ diffuse\\ pulmonary\\ fibrosis\\ primarily\\ affecting\\ the\\ upper\\ lung\\ zones\\.\ \(1\)\
\-\ stage\\ iv\\ sarcoidosis\ \(0\)\
\-\ although\\ there\\ are\\ over\\ 140\\ known\\ causes\\ of\\ pulmonary\\ fibrosis\\ some\\ of\\ the\\ most\\ common\\ are\\:\\ \ \(0\)\
\-\ pneumoconioses\ \(2\)\
\-\ systemic\\ lupus\\ erythematosis\ \(0\)\
\-\ rheumatoid\\ arthritis\ \(67\)\
\-\ sarcoidosis\ \(108\)\
\-\ tuberculosis\ \(73\)\
\-\ medications\\ \\(nitrofurantoin\\,\\ amiodarone\\,\\ cyclophosphamide\\,\\ methotrexate\\,\\ bleomycin\\)\ \(0\)\
\-\ idiopathic\ \(111\)\
\-\ the\\ patient\\ presented\\ with\\ worsening\\ shortness\\ of\\ breath\\ and\\ dyspnea\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ erythematosis\\:\\ 0\\.11301946697392946\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.09896644529141634\ \(0\)\
\-\ nitrofurantoin\\:\\ 0\\.09893469404228702\ \(0\)\
\-\ fibrosis\\:\\ 0\\.09756110589410877\ \(0\)\
\-\ pulmonary\\:\\ 0\\.09602116577769475\ \(0\)\
\-\ pneumoconioses\\:\\ 0\\.09238564758374869\ \(0\)\
\-\ bleomycin\\:\\ 0\\.09238564758374869\ \(0\)\
\-\ restrictive\\:\\ 0\\.0834991452688776\ \(0\)\
\-\ amiodarone\\:\\ 0\\.0834991452688776\ \(0\)\
\-\ breath\\:\\ 0\\.08192609123716277\ \(0\)\
\-\ cyclophosphamide\\:\\ 0\\.0791853986455287\ \(0\)\
\-\ 140\\:\\ 0\\.07747345771444508\ \(0\)\
\-\ zones\\:\\ 0\\.07461264295400649\ \(0\)\
\-\ methotrexate\\:\\ 0\\.06984900761512851\ \(0\)\
\-\ dry\\:\\ 0\\.06510062571388628\ \(0\)\
\-\ lupus\\:\\ 0\\.06450421525702868\ \(0\)\
\-\ crackles\\:\\ 0\\.06365860028533897\ \(0\)\
\-\ affecting\\:\\ 0\\.06096250530025742\ \(0\)\
\-\ primarily\\:\\ 0\\.05749724466256625\ \(0\)\
\-\ tests\\:\\ 0\\.0573296538732412\ \(0\)\
\-\ diffusely\\:\\ 0\\.05532959940559273\ \(0\)\
\-\ systemic\\:\\ 0\\.052411930836591764\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.05218700378978523\ \(0\)\
\-\ dyspnea\\:\\ 0\\.05185684358334401\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.051748652959679085\ \(0\)\
\-\ idiopathic\\:\\ 0\\.04994278843767145\ \(0\)\
\-\ medications\\:\\ 0\\.04886630920539794\ \(0\)\
\-\ arthritis\\:\\ 0\\.04680426218003826\ \(0\)\
\-\ stage\\:\\ 0\\.04673121062728649\ \(0\)\
\-\ function\\:\\ 0\\.04644309709072164\ \(0\)\
\-\ shortness\\:\\ 0\\.04609182819087402\ \(0\)\
\-\ sounds\\:\\ 0\\.04369675195520999\ \(0\)\
\-\ worsening\\:\\ 0\\.04313435859488202\ \(0\)\
\-\ causes\\:\\ 0\\.04264847048474117\ \(0\)\
\-\ pattern\\:\\ 0\\.04187746588552921\ \(0\)\
\-\ iv\\:\\ 0\\.03997980689052684\ \(0\)\
\-\ although\\:\\ 0\\.03699909334072569\ \(0\)\
\-\ known\\:\\ 0\\.03466732159569\ \(0\)\
\-\ some\\:\\ 0\\.03326831094700973\ \(0\)\
\-\ diffuse\\:\\ 0\\.033166761799683524\ \(0\)\
\-\ decreased\\:\\ 0\\.032573800034930246\ \(0\)\
\-\ lung\\:\\ 0\\.03173280923383008\ \(0\)\
\-\ are\\:\\ 0\\.02986856083409235\ \(0\)\
\-\ presented\\:\\ 0\\.02986355942336422\ \(0\)\
\-\ common\\:\\ 0\\.02867009246097945\ \(0\)\
\-\ over\\:\\ 0\\.027892853719743108\ \(0\)\
\-\ upper\\:\\ 0\\.02643692955600921\ \(0\)\
\-\ most\\:\\ 0\\.025292758227283024\ \(0\)\
\-\ there\\:\\ 0\\.01630404559570498\ \(0\)\
\-\ \\:\\:\\ 0\\.01449070276911109\ \(0\)\
\-\ \\,\\:\\ 0\\.013882567462424993\ \(0\)\
\-\ patient\\:\\ 0\\.010981947832261384\ \(0\)\
\-\ on\\:\\ 0\\.009280654004684976\ \(0\)\
\-\ \\(\\:\\ 0\\.009261047772357187\ \(0\)\
\-\ \\)\\:\\ 0\\.009147919129657758\ \(0\)\
\-\ the\\:\\ 0\\.0053172801809086845\ \(0\)\
\-\ a\\:\\ 0\\.005084612843828221\ \(0\)\
\-\ and\\:\\ 0\\.004615615531595345\ \(0\)\
\-\ of\\:\\ 0\\.004480915415307247\ \(0\)\
\-\ with\\:\\ 0\\.003000107079227942\ \(0\)\
\-\ \\.\\:\\ 0\\.0013653667729748569\ \(0\)\
